ArticleOncology letters2025
Primary squamous thyroid cancer: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary squamous cell carcinoma of the thyroid (PSCCT) is a rare malignancy characterized by low incidence, high aggressiveness and poor prognosis, with no established standardized treatment guidelines. The present case involves a 66-year-old female who presented with a painless left neck mass discovered incidentally in July 2023. The mass progressed over two months, accompanied by dyspnea. In September 2023, surgical intervention confirmed a poorly differentiated thyroid carcinoma (6.0×5.0 cm, invading the anterior cervical muscles; Ki-67 ≈60%, mutant-type p53) in the left lobe and nodular goiter in the right lobe. The patient underwent left radical thyroidectomy and right lobectomy (no lymph node metastasis detected in 9 central compartment nodes). Postoperative PD-L1 testing revealed high expression (CPS=50). From November 2023 to February 2024, the patient completed 6 cycles of chemotherapy (albumin-bound paclitaxel + carboplatin) combined with immunotherapy (tislelizumab). Partial radiotherapy (16/25 fractions) was initiated in March 2024 but discontinued due to radiation-induced mucositis and leukopenia. Follow-up in June 2024 demonstrated complete response (CR) with no evidence of recurrence. This case achieved complete response (CR) through multidisciplinary integrated therapy, providing clinical evidence for PSCCT treatment optimization. Given the rarity and therapeutic uncertainty of PSCCT, our study highlights: The critical value of immunohistochemistry (CK19+, CK5/6+, TTF-1-, TG-) in differential diagnosis; Potential benefits of immunotherapy in PD-L1-high expressors; The necessity of combining surgery with systemic therapies and demand for individualized strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.